Clinical Trials

Thoracical Tumors

Recruitment stopped
Ongoing Recruitment

GO adjuvant 29527 / GO29527

(adjuvant)
Title:A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
Indication:Lung Neoplasms Carcinoma, Non-Small-Cell Lung
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02486718
EudraCT: 2014-003205-15 (siehe EU klinisches Studienregister)

I4T-MC-JVCY

(first-line)
Title:A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Indication:Carcinoma, Non-Small-Cell Lung, EGFR mutation, Stage IV, First-line Therapy
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02411448
EudraCT: 2014-004824-22 (siehe EU klinisches Studienregister)

CINC wt-Studie (Novartis CINC280A2201)

(second-line)
Title:A Phase II, Multicenter, Three-cohort Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease
Indication:Carcinoma, Non-Small-Cell Lung
Type of study:Phase II
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Michael Thomas (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02414139
EudraCT: NCT02414139 (siehe EU klinisches Studienregister)

Novartis CINC Kombi (CINC280X2105C)

(second-line)
Title:A Phase Ib/II, Multicenter, Open-label Study of EGF816 in Combination With INC280 in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer.
Indication:NSCLC, EGFR mutation, Stage IIIB/IV, Second-line + (First-line Therapy partly possible)
Type of study:Phase I/II
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Michael Thomas (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02335944
EudraCT: 2014-000726-37 (siehe EU klinisches Studienregister)

PET-CT__PET-MRT bei BC

(diagnostisch, Screening)
Title:Vergleich der diagnostischen Genauigkeit von FDG-PET/CT und FDG-PET/MRT einschließlich Diffusionsgewichteter MRT beim präoperativen Staging von Patienten mit Nicht-kleinzelligem Bronchialkarzinom.
Indication:n.a.
Type of study:Phase N/A
Contact: Radiologie DKFZ (Kontaktperson)
[-]
Investigator: Prof. Dr. Heinz-Peter Schlemmer (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

INKA-Studie

(radiologisch)
Title:Ionentherapie bei nicht-kleinzelligen Pancoast-Tumoren im trimodalen Behandlungskonzept: Die INKA-Studie
Indication:Lunge
Type of study:Phase N/A
Contact: Prof. Dr. med. Jürgen Debus (Kontaktperson)
[juergen.debus@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Klaus Herfarth (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

ATLANTIS (PM1183-C-003-14)

Title:Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)
Indication:Lung NeoplasmsSmall Cell Lung Carcinoma
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02566993
EudraCT: 2015-004861-97 (siehe EU klinisches Studienregister)

BI 1199.93 / LUME Meso

Title:LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma
Indication:Mesothelioma
Type of study:Phase II/III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01907100
EudraCT: 2012-005201-48 (siehe EU klinisches Studienregister)

CA209-743 / BMS Meso

Title:A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma
Indication:Mesothelioma
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02899299
EudraCT: 2016-001859-43 (siehe EU klinisches Studienregister)

D419QC00001 / CASPIAN

Title:A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease (Stage IV) Small-Cell Lung Cancer (SCLC)
Indication:CarcinomaLung NeoplasmsSmall Cell Lung Carcinoma
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03043872
EudraCT: 2016-001203-23 (siehe EU klinisches Studienregister)

DURATION / AIO-YMO/TRK-0416

Title:Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
Indication:CarcinomaLung NeoplasmsCarcinoma, Non-Small-Cell LungAdenocarcinoma
Type of study:Phase II
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03345810
EudraCT: 2016-003963-20 (siehe EU klinisches Studienregister)

FORCE

Title:Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC
Indication:CarcinomaLung NeoplasmsAdenocarcinomaCarcinoma, Non-Small-Cell Lung
Type of study:Phase II
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr.med. Farastuk Bozorgmehr (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03044626
EudraCT: 2015-005741-31 (siehe EU klinisches Studienregister)

Lusi-Studie

Title:Lung cancer screening intervention trial for the early detection of lung cancer. Randomized controlled screening trial with multislice CT scanning in Germany - COPD Auswertung
Indication:Lung
Type of study:Phase N/A
Contact: Prof. Dr. med. Claus Peter Heußel (Kontaktperson)
[clauspeter.heussel@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Claus Peter Heußel (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

MERU / M16-298

Title:A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)
Indication:Lung Neoplasms Small Cell Lung Carcinoma
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03033511
EudraCT: 2016-003503-64 (siehe EU klinisches Studienregister)

MK-3475-604 / Pembro SCLC

Title:A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects With Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)
Indication:Lung NeoplasmsSmall Cell Lung Carcinoma
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03066778
EudraCT: 2016-004309-15 (siehe EU klinisches Studienregister)

POSEIDON / D419MC00004

Title:A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC)
Indication:Lung NeoplasmsCarcinoma, Non-Small-Cell Lung
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Michael Thomas (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03164616
EudraCT: 2017-000920-81 (siehe EU klinisches Studienregister)

TAHOE / M16-289

Title:A Randomized, Open-label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for High DLL3 Expressing Small Cell Lung Cancer (SCLC) Subjects With First Relapse/Recurrence Following Front-Line Platinum-Based Chemotherapy (TAHOE)
Indication:Lung NeoplasmsSmall Cell Lung Carcinoma
Type of study:Phase III
Contact: Jens Tillmann (Kontaktperson)
[Thoraxklinik.Studienkoordination-Onkologie@med.uni-heidelberg.de]
Investigator: Dr. med. Helge Bischoff (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03061812
EudraCT: 2016-003726-17 (siehe EU klinisches Studienregister)